MedTrace Logo

Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma

NCT03358628 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-11-30

No results posted yet for this study

Summary

By obtaining clinical specimens from participants with high-grade bone and soft tissue sarcomas to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with individualized cancer treatment options

Conditions

Interventions

OTHER

Molecular Profiling & In Vivo drug testing in PDX

Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Wei Guo, MD, PhD · Peking University People's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2020-01-31
Completion
2025-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358628 on ClinicalTrials.gov